logo-loader

Argentex encouraged as trading continues to improve

Published: 04:14 20 Jan 2021 EST

Argentex - Argentex encouraged as trading continues to improve

Argentex Group PLC (LON:AGFX) told investors that trading has continued to improve, since its last update in November.

The company, which provides bespoke foreign exchange services, noted that the full effect of the latest coronavirus (COVID-19) lockdown has yet to be felt but suggested a more positive outlook for the coming months.

In a trading update, the group said that “the recent Brexit trade agreement and the successful implementation of the vaccine programme for Covid-19 provides the board of Argentex with confidence that this encouraging trend, driven by a return to historic client trading behaviour, will continue for the remainder of the financial year to 31 March 2021.”

The company also announced the appointment of Jo Stent as chief financial officer with effect from February 1, replacing Sam Williams, who is leaving Argentex to pursue other opportunities.

Stent has been a senior finance professional for 25 years and was most recently chief financial officer of golf’s European Tour and Ryder Cup Europe.

At the same time, joint chief executive Carl Jani is taking a leave of absence for health reasons with immediate effect, and, fellow joint chief executive Harry Adams will be sole chief executive.

"We are delighted to have attracted someone of Jo's calibre to Argentex,” Adams said in the statement.

“Her financial expertise and experience in global businesses will be a huge benefit to us as we continue to realise our growth ambitions. This is an exciting time for us as trading volumes return to pre-pandemic levels."

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 4 minutes ago